CytomX Therapeutics, Inc.
CTMX
$2.98
$0.041.36%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 1,447.21% | -88.88% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1,447.21% | -88.88% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 1,447.21% | -88.88% | |||
| SG&A Expenses | 70.80% | -2.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.03% | 18.70% | |||
| Operating Income | 21.73% | -59.39% | |||
| Income Before Tax | 31.25% | -86.69% | |||
| Income Tax Expenses | 9.26% | -6.90% | |||
| Earnings from Continuing Operations | 31.17% | -86.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 31.17% | -86.31% | |||
| EBIT | 21.73% | -59.39% | |||
| EBITDA | 21.12% | -57.49% | |||
| EPS Basic | 40.83% | -101.74% | |||
| Normalized Basic EPS | 26.41% | -62.20% | |||
| EPS Diluted | 41.23% | -94.56% | |||
| Normalized Diluted EPS | 26.41% | -62.20% | |||
| Average Basic Shares Outstanding | 4.47% | 2.84% | |||
| Average Diluted Shares Outstanding | 4.47% | 2.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||